NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CDNA Stock Alerts $7.56 -0.42 (-5.26%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$7.53▼$7.8050-Day Range$7.85▼$12.0852-Week Range$4.80▼$12.93Volume555,244 shsAverage Volume893,064 shsMarket Capitalization$391.46 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside78.6% Upside$13.50 Price TargetShort InterestHealthy9.54% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.79Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.59) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.84 out of 5 starsMedical Sector298th out of 907 stocksDiagnostics & Research Industry1st out of 2 stocks 3.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCareDx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.54% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in CareDx has recently decreased by 9.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 3.2 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CareDx this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat Follows4 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.59) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesApril 19, 2024 | businesswire.comCareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)April 19, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Stock Rating Reaffirmed by StephensApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 19, 2024 | investing.comCareDx shares hold as new CEO appointment confirmedApril 18, 2024 | investing.comCareDx names John W. Hanna as new President and CEOApril 16, 2024 | businesswire.comCareDx Appoints John W. Hanna as its New President and Chief Executive OfficerApril 9, 2024 | finance.yahoo.comCareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation MeetingApril 9, 2024 | businesswire.comCareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation MeetingApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 26, 2024 | msn.comReplimune Group announces CEO transitionMarch 16, 2024 | finance.yahoo.comCDNA Apr 2024 10.000 putMarch 16, 2024 | finance.yahoo.comCDNA Apr 2024 2.500 callMarch 14, 2024 | msn.comUroGen Pharma reports mixed Q4 results; initiates FY24 outlookMarch 11, 2024 | businesswire.comCareDx Appoints Bryan Riggsbee to Its Board of DirectorsMarch 6, 2024 | markets.businessinsider.comCareDx Hold Rating: Balancing Modest Growth Prospects with Operational UncertaintiesMarch 4, 2024 | finance.yahoo.comCDNA Mar 2024 17.500 callMarch 1, 2024 | finance.yahoo.comCareDx Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 29, 2024 | finance.yahoo.comCareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | msn.comCareDx Non-GAAP EPS of -$0.17 beats by $0.10, revenue of $65.6M beats by $1.54MFebruary 28, 2024 | finance.yahoo.comCareDx Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 28, 2024 | finance.yahoo.comCareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023February 27, 2024 | finance.yahoo.comCareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors ConferenceFebruary 27, 2024 | benzinga.comEarnings Outlook For CareDxFebruary 27, 2024 | businesswire.comCareDx to Participate in the Raymond James & Associates' 45th Annual Institutional Investors ConferenceFebruary 22, 2024 | benzinga.comCareDx Stock (NASDAQ:CDNA), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comCareDx to Report Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | businesswire.comCareDx to Report Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees635Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+76.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-67.88% Pretax Margin-67.83% Return on Equity-51.40% Return on Assets-37.85% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.77 Sales & Book Value Annual Sales$280.32 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$4.83 per share Price / Book1.59Miscellaneous Outstanding Shares51,780,000Free Float49,604,000Market Cap$396.63 million OptionableOptionable Beta1.42 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMr. John Walter Hanna Jr. (Age 44)President, CEO & Director Ms. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsCelcuityNASDAQ:CELCSera PrognosticsNASDAQ:SERACastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTGenetronNASDAQ:GTHView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 219,774 shares on 4/24/2024Ownership: 0.689%Sumitomo Mitsui Trust Holdings Inc.Sold 126,561 shares on 4/19/2024Ownership: 5.308%Allspring Global Investments Holdings LLCBought 18,481 shares on 4/18/2024Ownership: 0.036%Los Angeles Capital Management LLCBought 21,892 shares on 4/5/2024Ownership: 0.500%Bullseye Asset Management LLCBought 5,000 shares on 2/17/2024Ownership: 0.323%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions Should I buy or sell CareDx stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDNA shares. View CDNA analyst ratings or view top-rated stocks. What is CareDx's stock price target for 2024? 4 brokerages have issued 12-month price targets for CareDx's shares. Their CDNA share price targets range from $12.00 to $15.00. On average, they anticipate the company's share price to reach $13.50 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts. How have CDNA shares performed in 2024? CareDx's stock was trading at $12.00 at the start of the year. Since then, CDNA stock has decreased by 37.0% and is now trading at $7.56. View the best growth stocks for 2024 here. Are investors shorting CareDx? CareDx saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 4,690,000 shares, a decline of 9.5% from the March 31st total of 5,180,000 shares. Based on an average daily trading volume, of 878,300 shares, the short-interest ratio is currently 5.3 days. Currently, 9.5% of the company's stock are short sold. View CareDx's Short Interest. When is CareDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CDNA earnings forecast. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) released its earnings results on Wednesday, February, 28th. The company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $1.97. The business earned $65.57 million during the quarter, compared to analysts' expectations of $63.66 million. CareDx had a negative trailing twelve-month return on equity of 51.40% and a negative net margin of 67.88%. The business's quarterly revenue was down 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.34) earnings per share. What ETFs hold CareDx's stock? ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and Jacob Forward ETF (JFWD).Global X Genomics & Biotechnology ETF (GNOM). What guidance has CareDx issued on next quarter's earnings? CareDx issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $260.0 million-$274.0 million, compared to the consensus revenue estimate of $260.6 million. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA). Who are CareDx's major shareholders? CareDx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (5.31%), Assenagon Asset Management S.A. (0.69%), Los Angeles Capital Management LLC (0.50%) and Allspring Global Investments Holdings LLC (0.04%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CDNA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
